LIVN Stock Analysis: Buy, Sell, or Hold?
LIVN - LivaNova PLC Ordinary Shares
$78.74
0.53 (0.68%)
▲
5d:
-4.23%
30d:
+0.17%
90d:
+6.93%
HOLD
MODERATE Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When LIVN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: LIVN is fairly valued with market pricing in 2.9% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: LIVN is fairly valued with market pricing in 2.9% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$95.61
Based on 5.7% avg growth
INTRINSIC VALUE TODAY
$59.37
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: LIVN is currently trading at $78.74, which is considered slightly low relative to its 30-day fair value range of $77.86 to $81.99. The stock's valuation (Forward PE: 16.8) is in line with its historical norms (15.5). At these levels, the market is pricing in 2.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, LIVN is in a strong uptrend. Immediate support is located at $75.04, while resistance sits at $82.70.
Market Sentiment: LIVN scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (2th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $88.80 (+12.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LIVN is in a strong uptrend. Immediate support is located at $75.04, while resistance sits at $82.70.
Market Sentiment: LIVN scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (2th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $88.80 (+12.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$77.86 -
$81.99
Company Quality Score
56/100
(HOLD)
Options IV Signal
2th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
64.2%
Protect Your Profits
Holding LIVN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 2th percentile)
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($88.80)
- NEUTRAL: Market pricing in 2.9% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$77.86 -
$81.99
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$4.49
(5.7%)
Support & Resistance Levels
Support Level
$75.04
Resistance Level
$82.70
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.84
Wall Street Target
$88.80
(+12.8%)
Revenue Growth (YoY)
10.8%
Earnings Growth (YoY)
287.8%
Profit Margin
12.8%
Valuation Premium vs History
+2.9% premium
PE vs Historical
16.8 vs 15.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.9%
(market-implied from PE analysis)
1-Year Target
$81.02
(+3%)
2-Year Target
$83.37
(+6%)
3-Year Target
$85.79
(+9%)
3-Yr Target (if PE normalizes)
(PE: 17→16)
PE COMPRESSION
$78.98
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 7.4%)
$116.19
(+48%)
Base:
(SPY PE: 16.8, Growth: 7.4%)
$97.47
(+24%)
Bear:
(PE: 14.3, Growth: 7.4%)
$82.85
(+5%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (23x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 23.07 | Current EPS (TTM): $3.39
Bull Case
$118.68
(+51%)
Analyst growth 38.0%, PE expands to 25.4
Base Case
$107.90
(+37%)
Market implied 38.0%, PE stable at 23.1
Bear Case
$53.18
(-33%)
Severe decline -20.0%, PE contracts to 19.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 22, 2026 8:32 PM ET
Data refreshes hourly during market hours. Next update: 9:32 PM
Data refreshes hourly during market hours. Next update: 9:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LIVN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 53 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 48 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 31 SELL |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$119 | 37 SELL |
Advanced LIVN Option Strategies
Professional options setups generated by AI based on today's LIVN price and gamma walls.
